Continuous VEGF Expression Throughout the Tumor Life Cycle
As demonstrated in preclinical models, VEGF plays a central role in tumor development
VEGF may affect tumor vasculature in 3 essential ways1:
- Early in tumor development, VEGF may help establish new vasculature.
- As the vasculature network develops, VEGF may continue to help new vasculature grow, providing the blood supply needed to drive further tumor growth and metastasis.
- Throughout tumor development, VEGF may also help existing vasculature survive, allowing tumors to sustain their metabolic requirements over their entire life cycle.
As the tumor develops, it may begin to activate secondary angiogenic pathways, such as basic fibroblast growth factor (bFGF), transforming growth factor beta (TGFβ), placental growth factor (PlGF), and platelet-derived endothelial cell growth factor (PD-ECGF). As these secondary pathways emerge, VEGF continues to be expressed and remains one of the critical mediators of angiogenesis (Figure 1).2-8
Figure 1. Continuous VEGF expression throughout tumor development2-4
The role of VEGF across tumor types, as demonstrated in preclinical models
Expression of VEGF has been observed across a range of tumor types and has been widely correlated with tumor development and/or poor cancer prognosis.9-11
- Ellis LM, Hicklin DJ. Nat Rev Cancer. 2008;8:579-591. PMID: 18596824
- Folkman J. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Vol 2. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:2865-2882.
- Hanrahan V, Currie MJ, Gunningham SP, et al. J Pathol. 2003;200:183-194. PMID: 12754739
- Fontanini G, Vignati S, Boldrini L, et al. Clin Cancer Res. 1997;3:861-865. PMID: 9815760
- Rini BI, Small EJ. J Clin Oncol. 2005;23:1028-1043. PMID: 15534359
- Jain RK, Duda DG, Clark JW, Loeffler JS. Nat Clin Pract Oncol. 2006;3:24-40. PMID: 16407877
- Bergers G, Brekken R, McMahon G, et al. Nat Cell Biol. 2000;2:737-744. PMID: 11025665
- Inoue M, Hager JH, Ferrara N, et al. Cancer Cell. 2002;1:193-202. PMID: 12086877
- Ferrara N. Endocr Rev. 2004;25:581-611. PMID: 15294883
- Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23:1011-1027. PMID: 15585754
- Margolin K. Curr Oncol Rep. 2002;4:20-28. PMID: 11734110